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ABSTRACT
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence 
of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can 
respond to BRAF inhibitors. Unfortunately, the lack of adequate archival tissue often 
precludes BRAF testing. We hypothesized that cell-free DNA (cfDNA) from plasma 
or urine can offer an alternative source of biologic material for testing. We tested 
for BRAF V600E mutation in cfDNA from the plasma and urine of 6 ECD patients. In 
patients with available archival tissue, the result of BRAF mutation analysis was 
concordant with plasma and urine cfDNA results in all 3 patients (100% agreement, 
kappa 1.00). In all 6 patients, BRAF mutation analysis of plasma and urine cfDNA was 
concordant in 5 of 6 patients (83% agreement, kappa 0.67). Testing for BRAF V600E 
mutation in plasma and urine cfDNA should be further investigated as an alternative 
to archival tissue mutation analysis.
INTRODUCTION
Erdheim-Chester disease (ECD) is a rare form of 
non-Langerhans cell histiocytosis affecting adults, which 
is associated with xanthogranulomatous infiltration of 
foamy macrophages.[1-3] ECD is deemed to be driven 
by increased signaling within the mitogen-activated-
protein kinase pathway. Advances in genome sequencing 
technologies led to the identification of BRAF V600E 
mutations in at least 50% of patients with ECD.[4] 
Furthermore, preliminary results suggest that patients 
with ECD and BRAF mutations can benefit from targeted 
inhibition of BRAF protein with BRAF inhibitors.[5] 
Unfortunately, archival tissue often does not provide an 
adequate amount of DNA for molecular testing. Therefore, 
novel technologies allowing mutation analysis to be 
performed using alternative sources of biologic material 
are needed.[6] 
Cell-free DNA (cfDNA) is released to the circulation 
from cells undergoing apoptosis, necroptosis and active 
secretion and has been identified in the plasma and urine 
of patients with cancer.[7, 8] Detecting and quantifying 
the amount of mutant cfDNA fragments harboring specific 
mutations can be used as an alternative to tissue testing. 
Some data suggest that the amount of mutant DNA 
correlates with tumor burden and can be used to identify 
the emergence of resistant mutations.[9-14] The concept 
of mutation testing from urine cfDNA has been assessed 
in a pilot study in patients with advanced colorectal cancer 
and other colorectal diseases in which KRAS mutations in 
urine cfDNA were concordant in 95% of cases with KRAS 
mutation status in tumor tissue.[15] We examine in our 
study whether urine and plasma cfDNA can be used as an 
alternative to tissue biopsies for BRAF V600E mutation 
testing in patients with ECD. 
RESULTS AND DISCUSSION
A total of 6 patients with ECD were enrolled. Their 
median age at diagnosis was 46 years (range, 26 to 71 
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years) and most patients were white 4 (67%) and male 4 
(67%). Tumor tissue BRAF V600E mutation testing with 
targeted next-generation sequencing and/or allele-specific 
PCR in the CLIA-certified laboratory was requested for all 
6 patients, but 3 patients had insufficient tissue samples, 
precluding mutation analysis (Table 1). BRAF V600E 
mutations were detected in 2 (67%) of 3 tested tumor 
tissue samples, 3 (50%) of 6 plasma cfDNA samples and 
4 (67%) of urine cfDNA samples (Figure 1). Observed 
agreements were 100% (3 of 3, kappa 1.00) for tumor 
tissue and plasma cfDNA, 100% (3 of 3, kappa 1.00) for 
tumor tissue and urine cfDNA, and 83% (5 of 6, kappa 
0.67) for plasma cfDNA and urine cfDNA (Table 1). In 
addition, there were no BRAF V600E mutations in plasma 
and urine cfDNA from 14 patients with metastatic cancer 
with confirmed wt BRAF in their tumor tissue (data not 
shown). Finally, only one patient (patient 1) was treated 
with a BRAF inhibitor; however, the treatment outcomes 
were not available at the time of analysis.
BRAF V600E mutations have been reported in more 
than 50% of patients with ECD.[4] In addition, preliminary 
data reveal encouraging activity of BRAF inhibitors such 
as vemurafenib in ECD patients with BRAF V600E 
mutations.[5] Mutation analysis of tumor tissue remains 
a gold standard for molecular analysis; however, in some 
disorders such as ECD, available tumor tissue often does 
not provide enough DNA for molecular analysis. In our 
experience, archival tissue testing for BRAF mutations is 
not feasible in up to 60% of patients.[6] This creates a 
major hurdle for further implementation of personalized 
therapies into the ECD therapeutic armamentarium since 
BRAF inhibitors in general can be effective in patients 
with BRAF mutations but detrimental in patients without 
them.[16] Therefore, there is a clear need for a new and 
easily obtainable source of material that can be used 
to analyze tumor molecular aberrations. [7, 8] cfDNA 
is released to the circulation from cells undergoing 
apoptosis, necroptosis and active secretion and has been 
identified in the plasma or urine of patients with cancer.[9-
14] Arguably, cfDNA can originate from multiple tumor 
sites and its molecular analysis may perhaps better reflect 
prevailing molecular aberrations.[9, 10] 
Our study suggests that mutation analysis of plasma 
and/or urine cfDNA from patients with ECD can be 
concordant with archival tissue and should be investigated 
as its alternative in furthering personalized therapy for 
patients whose tumor tissue is in short supply. 
METHODS
Patients with ECD were referred to the Clinical 
Center for Targeted Therapy at The University of 
Texas MD Anderson Cancer Center (MD Anderson) 
and prospectively enrolled starting in January 2013. 
Table 1: Urine and plasma cell-free DNA BRAF V600E mutations
 
 
 
Patient#
 
Age at 
diagnosis
 
 
Gender
 
 
Involvement
 
Urine BRAF
V600E/WT
 
Plasma BRAF
V600E/WT
 
Patient Tissue
BRAF status
 
 
1
 
 
59
 
 
Male
 
 
CNS, cardiac, bones, renal
 
V600E 
(22.590%
)
 
V600E 
(8.598%)
 
 
V600E
 
 
2*
 
 
43
 
 
Male
 
 
CNS,bones, renal
 
V600E 
(0.311%)
 
V600E 
(1.522%)
 
 
V600E
 
 
3
 
 
26
 
 
Male
 
 
Skin
 
Wild-type
(0.010%)
 
Wild-type
(0.063%)
 
 
Wild-type
 
 
4
 
 
71
 
 
Female
 
 
Bones, lymph nodes
 
V600E 
(0.159%)
 
Wild-type
(0.047%)
 
 
Unknown**
 
 
5
 
 
43
 
 
Female
 
 
CNS, bones
 
V600E 
(4.940%)
 
V600E 
(0.261%)
 
 
Unknown**
 
 
6
 
 
49
 
 
Male
 
 
CNS, cardiac, omentum, retroperitoneum
Wild-type 
indeterminate 
(0.079%)
 
Wild-type
(0.048%)
 
 
Unknown**
CNS; central nervous system
*Urine and plasma collected on different dates
** lnsuficient tissue for molecular analysis
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In addition, 14 patients with metastatic cancers with 
known wild-type (wt) BRAF in tumor tissue were used 
as a negative control group. Database registration of 
patients and pathology assessment were performed at MD 
Anderson. The study and all treatments were conducted 
in accordance with MD Anderson Institutional Review 
Board guidelines. A total of 10mL blood samples and 
approximately 60-120mL of urine from each consented 
patient were used for DNA isolation. 
Urine cfDNA was isolated by adding urine to an 
ion-exchange resin (GE Healthcare; Pittsburgh, PA). 
Nucleic acid was eluted with a chaotropic agent and 
subsequently purified by a silica-based resin (QIAGEN; 
Germantown, MD). The eluate was further purified using 
a specific molecular cutoff filter concentrator (Millipore; 
Billerica, MA), followed by a size exclusion column (Bio-
Rad; Hercules, CA). Plasma cfDNA was isolated using 
the QIAamp Circulating Nucleic Acid Kit (QIAGEN; 
Germantown, MD) according to the manufacturer’s 
instructions. 
Urine and plasma cfDNA were quantified by a 
droplet digital PCR (ddPCR; QX-100, BioRad; Hercules, 
CA) assay to a 44bp amplicon of RNase P, a single-copy 
gene. Quantified DNA (12.4ng to 60ng) was used for a 
two-step PCR assay for rare mutant allele detection of a 
31bp region containing BRAF V600E (Figure 1). The first 
step involved pre-amplification with two primers flanking 
the BRAF V600E locus, where both primers contain non-
complementary 5’ tags which hybridize to second round 
primers. A complementary blocking oligonucleotide 
suppressed wt BRAF amplification, achieving enrichment 
of the mutant BRAF V600E sequence within the pre-
amplification step. The second step entailed a duplex 
ddPCR reaction using FAM (V600E BRAF) and VIC 
(wt BRAF) TaqMan probes to enable differentiation of 
mutant versus wild-type quantification, respectively. The 
RainDrop ddPCR instrument (RainDance; Billerica, MA) 
was used for PCR droplet separation, fluorescent reading, 
and counting droplets containing mutant sequence, wt 
sequence, or unreacted probe. For a given patient sample, 
the assay reported BRAF V600E mutation fragments 
detected as a percentage of detected wt BRAF. Previous 
to this study, accuracy of the urine-based ddPCR BRAF 
V600E assay was verified in 89 urine specimens from 50 
healthy control samples (Precision Med; Solana Beach, 
CA) and 39 samples from 20 patients with known positive 
BRAF V600E mutation tissue biopsies as determined in 
a CLIA laboratory.[17] Thresholds for mutation detection 
in urine were determined by assessing these data using 
a classification tree. Minimizing the percentage of false 
negatives was given a higher importance than minimizing 
false positives. Thresholds were defined as no detection 
– wt (<0.05%), indeterminate (0.05% - 0.107%), and 
detected – V600E (>0.107%). For plasma detection, 
plasma from 13 patients with wt BRAF metastatic cancer 
was used to determine a threshold for detection of 
BRAF V600E mutations. For plasma, >0.094% mutant, 
equivalent to three standard deviations (0.021%) above 
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the mean of wt BRAF controls (0.031%), was considered 
positive for BRAF V600E mutation.
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